SLBST PHARMA INC.
ST PETERSBURG, FLORIDA

SLBST Pharma Inc., founded in August 2016, is based at 7901 4th St N, St Petersburg, FL 33702, and operates as a Florida-incorporated Limited Partnership. Led by CEO Dan Kim, who has over thirty years of experience in global pharmaceutical commercialization with notable deals involving Roche, Pfizer, and Novartis, the company focuses on strategic developments in various medical fields including infectious diseases, oncology, and medical devices. The team at SLBST Pharma is made up of experienced professionals like Chief Science Officer Beat Weidmann. Dr. Weidmann brings a wealth of knowledge from his past role at Novartis, particularly in the field of infectious disease research. He leads the company's scientific initiatives, focusing on R&D and technology that drive their mission forward. Vice President Yu Chen, PhD, plays a pivotal role in product development and alliances, creating partnerships across academia and industry to fund and advance SLBST Pharma’s projects. Together with other leaders, Dr. Chen is instrumental in forging paths through the scientific terrain to achieve progress in their drug development pursuits. At the heart of SLBST Pharma's efforts are innovative solutions for endometriosis, a prevalent condition affecting women worldwide. They harness groundbreaking discoveries related to autophagy inhibitors like hydroxychloroquine from research at the University of South Florida (USF). This work is integral to their ambition of advancing treatments in this area. The company keeps stakeholders informed and engaged through its website, www.slbstpharma.com, while progressing under the guidance of key figures-CEO Dan Kim, President Mark Connell, and other board members, as evidenced by annual reports last updated on December 9, 2024. SLBST Pharma continues to build on their strategic vision with a Federal Employer Identification Number of 81-3548814.